ERBB2 and neoplasm: Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate; the DESTINY-Breast01 trial demonstrated that the drug had strong anti-tumor activity in pretreated patients with HER2 positive metastatic breast cancer, especially, those ones with BM [55].